MedDataX Logo

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

NCT ID: NCT01193595

Last Updated: 2014-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

\- To determine the maximum administered dose (MAD) and the maximum tolerated dose (MTD) of ombrabulin in combination with best tolerated dose of bevacizumab based on the incidence of related Dose Limiting Toxicities (DLTs).

Secondary Objectives:

* To assess the overall safety profile of the combination
* To characterize the pharmacokinetic (PK) profile of both ombrabulin and bevacizumab when given in combination
* To evaluate preliminary evidence of anti-tumor activity
* To assess the pharmacodynamic effect using (Dynamic Contrast Enhanced Ultra-Sound) DCE-US, measuring biomarkers

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The duration of the study for each patient will include an up to 28-day screening phase, 21-day study treatment cycles, an end of treatment visit with a follow-up period. Each patient will participate in only one dose group and will receive AVE8062 with bevacizumab every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms, Malignant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AVE8062/ bevacizumab

The combination of ombrabulin and bevacizumab will be administered every 3 weeks according to the following schedule: One day 1, ombrabulin will be administered as a 30 minutes intravenous (i.v) infusion. Bevacizumab will be administered as a 30-90 minutes i.v. infusion 24 hours after the end of ombrabulin infusion on day 2.

Group Type EXPERIMENTAL

Ombrabulin (AVE8062)

Intervention Type DRUG

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

bevacizumab

Intervention Type DRUG

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ombrabulin (AVE8062)

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Intervention Type DRUG

bevacizumab

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically proven solid malignant tumor at the first diagnosis with the exception of squamous non small cell lung cancer (NSCLC).
* Advanced neoplastic disease (i.e. metastatic or locally unresectable advanced disease)
* Presence of one measurable lesion at baseline in the MTD expanded cohort

Exclusion Criteria

* ECOG (Eastern cooperativeOncology Group) performance status \> 1
* Concurrent treatment with any other anticancer therapy
* Pericardial effusion requiring intervention (drainage)
* History of brain metastasis, spinal cord compression or carcinomatous meningitis or new evidence of brain metastasis on screening Computed tomography (CT) or Magnetic resonance imaging (MRI) scan
* Diagnosis of squamous Non Squamous Cell Lung Cancer (NSCLC) or with mixed cell type with predominant squamocellular histology
* Hormone sensitive prostate cancer
* Abdominal Radiotherapy
* Major surgery within the last month of study enrollment or surgical wound not fully healed before study enrollment
* High cumulative doses of anthracycline
* Inadequate organ function
* Inadequate hematology function or poor bone marrow reserve
* Any of the following within 6 months prior to study enrollment: peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease and diverticulitis
* Any history or underlying cardiac condition that may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sanofi

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Investigational Site Number 250001

Villejuif, , France

Site Status

Investigational Site Number 380002

Milan, , Italy

Site Status

Investigational Site Number 380001

Milan, , Italy

Site Status

Investigational Site Number 826001

Sutton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Italy United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009-017797-20

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TCD11379

Identifier Type: -

Identifier Source: org_study_id